Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

ImmunoCellular Therapeutics LTD: Thoughts on Managementís Plan to Move ICT-107 into Phase 3 (IMUC, Neutral, $1.02)

Investment Overview

ImmunoCellular and its dendritic cell cancer vaccine ICT-107 were written off as failures in December of 2013 after it…
Read more…